Critical Comparison: GeneNews (GNWSF) vs. Achieve Life Sciences (ACHV)

Share on StockTwits

GeneNews (OTCMKTS:GNWSF) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares GeneNews and Achieve Life Sciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GeneNews $410,000.00 40.00 -$2.94 million N/A N/A
Achieve Life Sciences $5.06 million 5.74 -$12.69 million ($3.61) -1.20

GeneNews has higher earnings, but lower revenue than Achieve Life Sciences.


This table compares GeneNews and Achieve Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GeneNews -2,524.26% N/A -151.10%
Achieve Life Sciences N/A -96.59% -79.41%

Analyst Ratings

This is a breakdown of recent ratings for GeneNews and Achieve Life Sciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GeneNews 0 0 0 0 N/A
Achieve Life Sciences 0 0 1 0 3.00

Achieve Life Sciences has a consensus price target of $12.00, suggesting a potential upside of 177.78%. Given Achieve Life Sciences’ higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than GeneNews.

Institutional and Insider Ownership

23.0% of Achieve Life Sciences shares are held by institutional investors. 6.8% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

GeneNews has a beta of 4.53, meaning that its share price is 353% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 2.93, meaning that its share price is 193% more volatile than the S&P 500.


Achieve Life Sciences beats GeneNews on 7 of the 11 factors compared between the two stocks.

GeneNews Company Profile

GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Receive News & Ratings for GeneNews Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneNews and related companies with's FREE daily email newsletter.